Cumberland Pharmaceuticals
CPIX
24 hedge funds and large institutions have $30.4M invested in Cumberland Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
6% more capital invested
Capital invested by funds: $28.6M → $30.4M (+$1.76M)
4% more funds holding
Funds holding: 23 → 24 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.19% less ownership
Funds ownership: 31.88% → 30.69% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
+$494K |
| 2 |
Renaissance Technologies
New York
|
+$308K |
| 3 |
BlackRock
New York
|
+$296K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$94.6K |
| 5 |
B
Bailard
Foster City,
California
|
+$88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$106K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$80.8K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$63K |
| 5 |
Morgan Stanley
New York
|
-$9.28K |
CPIX Hedge Fund Activity: Q2 2019 in Review
24 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2019, worth a combined $30.4M — up 6.2% from $28.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CPIX positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 6 trimmed.
The largest buyer was Ariel Investments, adding an estimated $494K. The largest seller was Stonepine Capital Management, cutting an estimated $2M.
- 24 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2019, up from 23 in Q1 2019.
- Funds reported $30.4M of Cumberland Pharmaceuticals stock for Q2 2019, up 6.2% quarter-over-quarter.
- 4 funds opened new Cumberland Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Cumberland Pharmaceuticals buyer in Q2 2019 was Ariel Investments, an estimated $494K added.
- The largest Cumberland Pharmaceuticals seller in Q2 2019 was Stonepine Capital Management, an estimated $2M sold.
Based on aggregated 13F filings for Q2 2019.